DUBLIN, Calif. & JENA, Germany--(BUSINESS WIRE)--Apr 14, 2012-- Medical technology provider Carl Zeiss Meditec announced that its OPMI PENTERO(R) 900 surgical microscope has won the highly-coveted red dot award: product design 2012 in the Life Science and Medicine category.

Only 62 of the 4,515 products entered this year were awarded "red dot: best of the best" in various categories. The 30-member international jury honored the industrial design of the surgical microscope for meeting the highest standards in nine strict adjudication criteria, including quality, innovation, ergonomics and functionality. The winning products will be honored at the awards ceremony to be held in Aalto Theater in Essen, Germany, on July 2, 2012.

Combining streamlined functionality and ergonomics with aesthetic appeal Introduced in 2011, the OPMI PENTERO 900 microscope is used by surgeons in operating theaters around the world to visualize tissue structures and blood vessels in microsurgical applications. During surgery, the flexible touchscreen monitor of OPMI PENTERO 900 can be precisely positioned to optimize viewing of high definition images and videos of the surgical field, supporting surgeons in live clinical demonstrations, resident teaching or patient documentation. The smooth, seamless appearance of the monitor's multi-joint swivel arm contributes to the overall, compact elegance of the OPMI PENTERO 900 microscope.

"We are honored to have won this prestigious award," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. "As product design aspects like ergonomics and ease of use can support surgeons highly in their everyday work, our objective is to optimize function as well as form." Intraoperative fluorescence options expand spectrum of possible applications In addition to its sleek, contemporary design, the OPMI PENTERO 900 remains at the forefront of medical technology. For example, various intraoperative fluorescence options that are integrated into the OPMI PENTERO 900 expand the spectrum of possible applications for the microscope in both surgery and research. Its latest intraoperative fluorescence module, the YELLOW 560TM option highlights fluorescent-stained tissue at a wavelength of 540 to 690 nm while rendering surrounding tissue in its natural color.

"When I look at the microscope and I look at the fluorescence, I think that what we've seen is that not only can we magnify our fields and do better surgery that's more precise and more accurate, but we can also bring in information through our visual system that wasn't there before and I think that will continue to become the future for both Carl Zeiss and neurosurgery," said Michael T. Lawton, MD, Chief of Vascular Neurosurgery at the University of California, San Francisco Medical Center. "As we find ways to image tumor cells, brain ischemia, whatever it is, we can then integrate that into our visual field and interpret that information into our operations and I think that will allow us to evolve our technique and our surgery through the years." Live presentations at the AANS 2012 Attendees of the American Association of Neurological Surgeons (AANS) congress in Miami, Florida April 14 to 18, 2012 may obtain a demonstration of the OPMI PENTERO 900's ergonomics and other advanced features at Carl Zeiss Meditec's booth ? 713.

Along with the OPMI PENTERO 900, the OPMI(R) VARIO 700 microscope will be featured at Carl Zeiss Meditec's AANS booth.

Further information is available at Brief profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on TecDax of the German stock exchange, is one of the world's leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumables. The company creates innovative visualization solutions in the field of microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In fiscal year 2010/11 (ended 30 September) the company's around 2,400 employees generated revenue of EUR 759 million.

The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. 35 percent of Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.

For more information, please go to: Photos/Multimedia Gallery Available: CONTACT: Carl Zeiss Meditec AG Petra Rettenmaier, +49 36 41 220-331 Director Corporate Communications Henriette Meyer, +49 36 41 220-106 Director Investor Relations KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA FLORIDA INDUSTRY KEYWORD: SURGERY TECHNOLOGY OTHER TECHNOLOGY HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES MEDICAL SUPPLIES SOURCE: Carl Zeiss Meditec Copyright Business Wire 2012 PUB: 04/14/2012 12:55 AM/DISC: 04/14/2012 12:55 AM